Amy D. Shapiro

Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

Marilyn J. Manco‐Johnson, Thomas C. Abshire, Amy D. Shapiro et al. · New England Journal of Medicine · 2007 · 1.9K citations · Full text

Medicine, Hematology, Orthopedic Surgery +13

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A

Johnny Mahlangu, Jerry S. Powell, Margaret V. Ragni et al. · Blood · 2013 · 441 citations · Full text

Medicine, Hematology, Molecular Biology +14

Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study

Steven W. Pipe, Midori Shima, Michaela Lehle et al. · The Lancet Haematology · 2019 · 385 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +5

A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group.

Bray Gl, Gomperts Ed, S Courter et al. · PubMed · 1994 · 353 citations

Medicine, Hematology, Pharmacotherapy +17

Complete Deficiency of Plasminogen-Activator Inhibitor Type 1 Due to a Frame-Shift Mutation

William P. Fay, Amy D. Shapiro, Judy L. Shih et al. · New England Journal of Medicine · 1992 · 277 citations · Full text

Medicine, Biochemistry, Molecular Biology +12